Rheumatoid arthritis: who works on it

One card per institution. Filter by target, by country, or show only institutions in EU-13 (Horizon Europe widening) countries.

• All targets
• JAK 9
• TNF 9
• STAT3 0
• IL-6 2
• PI3K 0
• NLRP3 0
• CD19 17
• MAPK 0
• HIF-1 0
• NRF2 0
• mTOR 0
• AKT 0
• IL-17 0
• STING 0
• RANKL 0
• PPAR 0
• COX-2 0
• IL-1 0
• TLR4 0
• CD20 2
• TP53 0
• ERK 0
• PD-1 1
• SIRT1 0
• BCMA 7
• GLP-1 0
• MMP-9 0
• CTLA-4 1
• CTNNB1 0
• GPX4 0
• JNK 0
• SGLT2 1
• VEGF 1
• CD40 0
• HMGB1 0
• AMPK 0
• APOE 0
• AQP4 0
• CCR5 0
• FGFR 0
• IL-15 1
• METTL3 0
• PKM2 0
• TYK2 0
• CD38 1
• CGRP 0
• CXCR4 0
• IDO1 0
• PD-L1 0
• TIGIT 0
• BTK 0
• CD47 0
• EGFR 0
• HDAC 0
• IDH 0
• IL-23 0
• IL-4 0
• KEAP1 0
• MEK 0
• MYC 0

EU-13 is a filter, not a ranking: it only narrows the list.

18 of 18+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Terminated

  CD40L Antagonism in Rheumatoid Arthritis (RA)

  NCT05306353· National Institute of Allergy and Infectious Diseases (NIAID)· Updated 20 Jul 2026

  “The study is being closed early due to insufficient participant enrollment across study sites.”Registry text, quoted unchanged. Source

• Terminated

  Tc 99m Tilmanocept Imaging for Early Prediction of Anti-TNFα Therapy Response in Moderate to Severe Active RA

  NCT05246280· Navidea Biopharmaceuticals· Updated 23 Jan 2025

  “Sponsor Decision”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)

  NCT07137598· Hoffmann-La Roche· Source

• Discontinuation of Disease-modifying Anti-rheumatic Drugs (DMARDs) in Rheumatoid Arthritis Patients Also Using TNF Inhibitors

  NCT07802678· Sint Maartenskliniek· Source

• Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis

  NCT05814627· AbbVie· Source

• CD40L Antagonism in Rheumatoid Arthritis (RA)

  NCT05306353· National Institute of Allergy and Infectious Diseases (NIAID)· Source

• A Study of Baricitinib in Participants With Rheumatoid Arthritis

  NCT04086745· Eli Lilly and Company· Source

• Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)

  NCT06440629· Diakonhjemmet Hospital· Source

• A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

  NCT03915964· Eli Lilly and Company· Source

• Major Adverse Cardiovascular Events (MACE) in Rheumatoid Arthritis Patient With Moderate to Severe Disease Activity Treated With Tofacitinib and Statins vs TNF Inhibitors: TOFSTAT CLINICAL TRIAL

  NCT07554820· Shaikh Zayed Hospital, Lahore· Source

• COVID-19 VaccinE Response in Rheumatology Patients

  NCT05080218· Jeffrey Curtis· Source

• Nonsurgical Periodontal Treatment Combined With Anti-TNF-α in Patients With Rheumatoid Arthritis and Periodontitis

  NCT06818045· Hatice Yemenoğlu· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 43
• Organoids 3
• Mendelian Randomization Analysis 97
• CRISPR-Cas Systems 1
• Gene Expression Profiling 121
• Sequence Analysis, RNA 17
• Exome Sequencing 2
• Proteomics 52
• Metabolomics 44
• Mass Spectrometry 7
• Flow Cytometry 33
• Immunohistochemistry 18
• Liquid Biopsy 1
• Xenograft Model Antitumor Assays 2
• Positron-Emission Tomography 5
• Magnetic Resonance Imaging 58
• Machine Learning 87
• Deep Learning 9
• Cohort Studies 160
• Genome-Wide Association Study 113

• Deep Learning-Based Comparison of Knee Minimum Joint Space Width in Patients With Rheumatoid Arthritis and Osteoarthritis Before Total Knee Arthroplasty.

  J Rheumatol, Aug 2026

• From subjective assessment to data-driven diagnosis: the AI revolution in multimodal early detection of Sjögren's disease.

  Front Immunol, Jul 2026

• Framework for Rheumatoid Arthritis Assessment Using Thermal Images Based on DnCNN-MLR Hybrid Algorithm and Joint Temperature Indexing.

  Sensors (Basel), Jul 2026

• Detecting inflammatory arthritis in hand smartphone photographs: development and validation of a computer vision model in clinical settings.

  Rheumatology (Oxford), Jun 2026

• GeneCytNet: an interpretable deep learning framework for rheumatoid arthritis classification and in silico cytokine perturbation modeling.

  Front Immunol, Mar 2026

• Sjögren's syndrome-focusassist: lymphocytic focus assessment in Sjögren's syndrome: a deep learning and spatial analysis approach.

  Diagn Pathol, Feb 2026

• Artificial Intelligence in Action: A Comprehensive Review on Machine and Deep Learning Methods in Sjögren's Syndrome Diagnosis.

  Int J Rheum Dis, Dec 2025

• CA-OCL and CHAN: A novel diagnostic framework for rheumatoid arthritis integrating contradiction-aware orthogonal contrastive learning with confidence-guided hierarchical attention.

  Artif Intell Med, Nov 2025

• Segmentation and Classification of Joint Space Narrowing in Rheumatoid Arthritis Using Deep Learning.

  Annu Int Conf IEEE Eng Med Biol Soc, Jul 2025

See which targets of this disease your abstract mentions, and go to the people working on them.